Skip to main content

Rosanna Paciucci Barzanti

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Rosanna Paciucci Barzanti

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Transcripció, traducció i mitosi en càncer de pròstata resistent a teràpia.TRAMIT-CAP (GRE)

IP: Rosanna Paciucci Barzanti
Collaborators: Anna Santamaria Margalef
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 16500
Reference: 2014 SGR 733
Duration: 01/01/2014 - 31/12/2016

Red Temática de Investigación Cooperativa en Cáncer - RTICC

IP: Jaume Reventós Puigjaner
Collaborators: Joan Morote Robles, Inés de Torres Ramirez, Maria Asuncion Perez Benavente, Eva Colas Ortega, Silvia Cabrera Diaz, Antonio Gil Moreno, Rosanna Paciucci Barzanti, Marina Rigau Resina, Carles Xavier Raventós Busquets, Jacques Planas Morin, Anna Santamaria Margalef
Funding agency: Instituto de Salud Carlos III
Funding: 229500
Reference: RD12/0036/0035
Duration: 01/01/2013 - 30/06/2017

Regulation of protein translation and Notch signaling by the protein PTOV1. Its relevance to cancer progression.

IP: Rosanna Paciucci Barzanti
Collaborators: Miriam Izquierdo Sans
Funding agency: EUROPEAN COMMISSION
Funding: 145080
Reference: INCOMED - FELLOW 1
Duration: 13/05/2013 - 12/05/2016

Translational reprogramming in cancer: identification of markers of aggressive metastatic tumors useful in the...

IP: Rosanna Paciucci Barzanti
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 7800
Reference: BA12/00078
Duration: 01/11/2012 - 31/01/2013

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Nerea Morilla Pérez

Nerea Morilla Pérez

Research technician
Clinical Neuroimmunology
Read more
Jorge  Knörr Giménez

Jorge Knörr Giménez

Predoctoral researcher
Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Piero Arturo Alberti Delgado

Piero Arturo Alberti Delgado

Predoctoral researcher
Hepato-bilio-pancreatic surgery (HBP) and liver transplantation
Read more
Ana Isabel Guerrero Perez

Ana Isabel Guerrero Perez

Research technician
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.